Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 Study | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 Study


Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo.

The confirmatory trial evaluated teprotumumab for the treatment of active thyroid eye disease.

The primary endpoint of the study was met, with 82.9% of 41 teprotumumab-treated patients achieving a 2 mm or more reduction of proptosis compared with 9.5% of 42 placebo patients, a statically significant difference (P < .001), according to a press release from Horizon Pharma.

All secondary endpoints were met in the study. A greater percentage of teprotumumab-treated patients experienced a 2 point or greater reduction in clinical activity score and a 2 mm or greater reduction in proptosis from baseline, with no deterioration in clinical activity score or proptosis in the fellow eye, compared with the placebo group.

Teprotumumab For Treatment Of Thyroid Eye Disease Meets Endpoints In Phase 3 Study
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close